Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook
Source: SeekingAlpha
2026-02-12 07:52:12 ET
More on Organon
- Organon: Deep Value With No Clear Catalysts
- Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Organon Non-GAAP EPS of $0.63 misses by $0.10, revenue of $1.51B in-line
- Organon Q4 Earnings Preview: Cautious view amid weak year
- Seeking Alpha’s Quant Rating on Organon
Read the full article on Seeking Alpha
For further details see:
Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook
Organon & Co.
NASDAQ: OGN
OGN Trading
-0.62% G/L:
$6.44 Last:
894,009 Volume:
$6.45 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
